Alteplase

Generic Name: Alteplase

Brand Names: Activase, Cathflo, Cathflo Activase

Drug Type: Biotech

Chemical Formula: -

CAS Number: 105857-23-6

Unique Ingredient Identifier: 1RXS4UE564

Background: Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. Alteplase is a purified gl...

Indication: Alteplase is indicated for the treatment of acute ischemic stroke (AIS) and for use in acute myocardial infarction (AMI) for the reduction of mortality and incidence of heart failure. Alteplase is also indicated for the lysis of acute massive pulmonary embolism, defined as acute pulmonary emboli obstructing blood flow to a lobe or multiple lung segments, and...

Associated Conditions: Acute Ischemic Stroke, Cardiac mortality, Heart Failure, Pulmonary Embolism Acute Massive, Central venous access device thrombosis

Associated Therapies: -

Clinical Trials

Impact of Tissue Plasminogen Activator (tPA) Treatment for an Atypical Acute Respiratory Distress Syndrome (COVID-19)

Phase 3

Withdrawn

Conditions: Acute Respiratory Distress Syndrome

Interventions: Drug: Ringer solution
Drug: Tissue plasminogen activator

First Posted Date: 2020-07-01

Last Posted Date: 2021-03-12

Lead Sponsor: Negovsky Reanimatology Research Institute

Registration Number: NCT04453371

Pulmonary Embolism International THrOmbolysis Study-3

Phase 3

Recruiting

Conditions: Pulmonary Embolism

Interventions: Drug: Alteplase
Drug: Placebo

First Posted Date: 2020-06-12

Last Posted Date: 2024-07-11

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 650

Registration Number: NCT04430569

Locations: 🇳🇱
Isala hospital, Zwolle, Netherlands
🇵🇱
Department of Cardiac and Vascular Diseases, Kraków, Poland
🇵🇱
University of Warmia Mazury in Olsztyn - School of Medicine, Olsztyn, Poland

and more 93 locations

Thrombolysis Outcome in Ischemic Stroke

Completed

Conditions: Mortality
Thrombolytic Therapy
Stroke, Acute
Alteplase

First Posted Date: 2020-03-16

Last Posted Date: 2020-07-09

Lead Sponsor: Mazandaran University of Medical Sciences

Target Recruit Count: 214

Registration Number: NCT04309357

Locations: 🇮🇷
Bu Ali Sina hospital , Mazandarn University of Medical Science, Sari, Iran, Islamic Republic of

SITS-IVT in Patients >80 Years Study

Completed

Conditions: Ischaemic Stroke

Interventions: Drug: Alteplase

First Posted Date: 2020-02-07

Last Posted Date: 2024-07-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1655

Registration Number: NCT04260347

Locations: 🇸🇪
Karolinska University Hospital, Stockholm, Sweden

Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: mutant pro-urokinase
Drug: Alteplase

First Posted Date: 2020-02-05

Last Posted Date: 2023-09-07

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 200

Registration Number: NCT04256473

Locations: 🇳🇱
DUMAS trial office, Rotterdam, Netherlands

Intravenous Thrombolysis Registry for Acute Ischemic Stroke in China

Withdrawn

Conditions: Ischemic Stroke

Interventions: Drug: Alteplase
Drug: Urokinase

First Posted Date: 2019-06-25

Last Posted Date: 2019-06-25

Lead Sponsor: General Hospital of Shenyang Military Region

Registration Number: NCT03997292

Locations: 🇨🇳
General Hospital of Shenyang Military Region, Shenyang, Liaoning, China

Standard-dose Apixaban AFtEr Very Low-dose ThromboLYSis for Acute Intermediate-high Risk Acute Pulmonary Embolism

Phase 4

Terminated

Conditions: Pulmonary Embolism Subacute Massive
Pulmonary Embolism With Acute Cor Pulmonale
Pulmonary Embolism
Pulmonary Embolism With Pulmonary Infarction
Right Ventricular Failure
Right Ventricular Dysfunction

Interventions: Drug: Alteplase
Drug: Placebo
Drug: Unfractionated heparin
Drug: Apixaban

First Posted Date: 2019-06-18

Last Posted Date: 2021-06-11

Lead Sponsor: Victor Tapson, MD

Target Recruit Count: 4

Registration Number: NCT03988842

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Alteplase Compared to Tenecteplase in Patients With Acute Ischemic Stroke

Phase 3

Completed

Conditions: Stroke, Acute
Thromboses, Intracranial

Interventions: Drug: Alteplase
Drug: Tenecteplase

First Posted Date: 2019-03-26

Last Posted Date: 2023-05-12

Lead Sponsor: University of Calgary

Target Recruit Count: 1600

Registration Number: NCT03889249

Locations: 🇨🇦
St. Michaels Hospital, Toronto, Ontario, Canada
🇨🇦
London Health Sciences, London, Ontario, Canada
🇨🇦
Hamilton Health Sciences General Hospital, Hamilton, Ontario, Canada

and more 19 locations

The Norwegian Tenecteplase Stroke Trial 2

Phase 3

Terminated

Conditions: Ischemic Stroke
Cerebrovascular Disorders
Stroke, Acute

Interventions: Drug: Alteplase
Drug: Tenecteplase

First Posted Date: 2019-02-26

Last Posted Date: 2023-09-15

Lead Sponsor: Haukeland University Hospital

Target Recruit Count: 201

Registration Number: NCT03854500

Locations: 🇳🇴
Haukeland University Hospital, Bergen, Norway

Argatroban Plus R-tPA for Acute Ischemic Stroke

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: rt-PA
Drug: Argatroban

First Posted Date: 2018-11-14

Last Posted Date: 2022-02-22

Lead Sponsor: General Hospital of Shenyang Military Region

Target Recruit Count: 808

Registration Number: NCT03740958

Locations: 🇨🇳
General Hospital of ShenYang Military Region, ShenYang, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy